Richard W. Pascoe net worth and biography

Richard Pascoe Biography and Net Worth

Chairman of KemPharm
Mr. Pascoe has served as a director of KemPharm since January 2014 and as KemPharm’s executive chairman since November 2021. He served as lead independent director at KemPharm from November 2014 to November 2021. Mr. Pascoe served as the president and chief executive officer of Histogen Inc, a biologics company, from January 2019 to November 2021. From March 2013 to January 2019, Mr. Pascoe was the chief executive officer and a director of Apricus Biosciences, Inc., a specialty pharmaceutical company. From August 2008 to March 2013, Mr. Pascoe was the president and chief executive officer and a director of Pernix Sleep, Inc. (formerly known as Somaxon Pharmaceuticals, Inc.), a specialty pharmaceutical company. Prior to Pernix, from 2005 to 2008, Mr. Pascoe worked for ARIAD Pharmaceuticals, Inc., a specialty pharmaceutical company, where he was most recently senior vice president and chief operating officer. Mr. Pascoe also serves as a director of Seelos Therapeutics, Inc, a specialty pharmaceutical company. Mr. Pascoe received his B.S. degree from the United States Military Academy at West Point.

What is Richard W. Pascoe's net worth?

The estimated net worth of Richard W. Pascoe is at least $111,449.34 as of January 13th, 2023. Mr. Pascoe owns 19,973 shares of KemPharm stock worth more than $111,449 as of February 7th. This net worth estimate does not reflect any other assets that Mr. Pascoe may own. Learn More about Richard W. Pascoe's net worth.

How do I contact Richard W. Pascoe?

The corporate mailing address for Mr. Pascoe and other KemPharm executives is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. KemPharm can also be reached via phone at (321) 939-3416 and via email at [email protected] Learn More on Richard W. Pascoe's contact information.

Has Richard W. Pascoe been buying or selling shares of KemPharm?

In the last ninety days, Richard W. Pascoe has bought $51,680.00 of KemPharm stock. Most recently, on Friday, January 13th, Richard W. Pascoe bought 9,500 shares of KemPharm stock. The stock was acquired at an average cost of $5.44 per share, with a total value of $51,680.00. Following the completion of the transaction, the chief executive officer now directly owns 19,973 shares of the company's stock, valued at $108,653.12. Learn More on Richard W. Pascoe's trading history.

Who are KemPharm's active insiders?

KemPharm's insider roster includes R. Clifton (CFO), Travis Mickle (CEO), Richard Pascoe (Chairman), and David Tierney (Director). Learn More on KemPharm's active insiders.

Are insiders buying or selling shares of KemPharm?

During the last twelve months, KemPharm insiders bought shares 8 times. They purchased a total of 22,535 shares worth more than $114,813.35. The most recent insider tranaction occured on January, 13th when CFO R. Laduane Clifton bought 635 shares worth more than $3,689.35. Insiders at KemPharm own 1.1% of the company. Learn More about insider trades at KemPharm.

Information on this page was last updated on 1/13/2023.

Richard W. Pascoe Insider Trading History at KemPharm

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/13/2023Buy9,500$5.44$51,680.0019,973View SEC Filing Icon  
5/18/2022Buy5,000$4.92$24,600.008,285View SEC Filing Icon  
11/30/2021Buy1,500$7.88$11,820.00View SEC Filing Icon  
8/18/2020Buy10,000$0.64$6,400.00
See Full Table

Richard W. Pascoe Buying and Selling Activity at KemPharm

This chart shows Richard W Pascoe's buying and selling at KemPharm by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

KemPharm Company Overview

KemPharm logo
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Read More

Today's Range

Now: $5.60
Low: $5.52
High: $5.69

50 Day Range

MA: $4.96
Low: $4.12
High: $6.27

2 Week Range

Now: $5.60
Low: $4.00
High: $6.92

Volume

98,890 shs

Average Volume

221,892 shs

Market Capitalization

$193.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.16